56 related articles for article (PubMed ID: 23091393)
1. How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians.
Sarpatwari A; Lu Z; Russo M; Zakoul H; Lee SB; Toyserkani GA; Zhou EH; LaCivita C; Shaw KHH; Zendel L; Dal Pan GJ; Kesselheim AS
Clin Pharmacol Ther; 2024 Jun; 115(6):1293-1303. PubMed ID: 38375585
[TBL] [Abstract][Full Text] [Related]
2. Revisiting the relationship between contact and physician attitudes toward patients with opioid use disorder.
Dhanani LY; Franz B; Hall TK
Addict Behav Rep; 2021 Dec; 14():100372. PubMed ID: 34938833
[TBL] [Abstract][Full Text] [Related]
3. Don't sell out safety: a call to preserve risk evaluation and mitigation strategies to reduce harm to patients and the public in the U.S.
Worthy SL
J Pharm Policy Pract; 2016; 9():2. PubMed ID: 26798484
[TBL] [Abstract][Full Text] [Related]
4. Provider perceptions of system-level opioid prescribing and addiction treatment policies.
Haffajee RL; French CA
Curr Opin Psychol; 2019 Dec; 30():65-73. PubMed ID: 30856591
[TBL] [Abstract][Full Text] [Related]
5. Long-Run Trends in Antidepressant Use Among Youths After the FDA Black Box Warning.
Kafali N; Progovac A; Hou SS; Cook BL
Psychiatr Serv; 2018 Apr; 69(4):389-395. PubMed ID: 29241433
[TBL] [Abstract][Full Text] [Related]
6. SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program.
Alford DP; Zisblatt L; Ng P; Hayes SM; Peloquin S; Hardesty I; White JL
Pain Med; 2016 Jan; 17(1):52-63. PubMed ID: 26304703
[TBL] [Abstract][Full Text] [Related]
7. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).
Hoffman KB; Demakas AR; Dimbil M; Tatonetti NP; Erdman CB
Drug Saf; 2014 Nov; 37(11):971-80. PubMed ID: 25255848
[TBL] [Abstract][Full Text] [Related]
8. Scientometric assessment of drugs for chronic pain, 1979-2013: rapid growth of publications, paucity of successful drugs.
Kissin I
J Pain Res; 2014; 7():505-14. PubMed ID: 25187736
[TBL] [Abstract][Full Text] [Related]
9. The damage done by the war on opioids: the pendulum has swung too far.
Atkinson TJ; Schatman ME; Fudin J
J Pain Res; 2014; 7():265-8. PubMed ID: 24872719
[No Abstract] [Full Text] [Related]
10. Assuring safety of inherently unsafe medications: the FDA risk evaluation and mitigation strategies.
Nelson LS; Loh M; Perrone J
J Med Toxicol; 2014 Jun; 10(2):165-72. PubMed ID: 24414251
[TBL] [Abstract][Full Text] [Related]
11. "Nonmedical" prescription opioid use in North America: a call for priority action.
Voon P; Kerr T
Subst Abuse Treat Prev Policy; 2013 Dec; 8():39. PubMed ID: 24289260
[TBL] [Abstract][Full Text] [Related]
12. The changing landscape of opioid prescribing: long-acting and extended-release opioid class-wide Risk Evaluation and Mitigation Strategy.
Gudin JA
Ther Clin Risk Manag; 2012; 8():209-17. PubMed ID: 22570553
[TBL] [Abstract][Full Text] [Related]
13. ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.
Cepeda MS; Coplan PM; Kopper NW; Maziere JY; Wedin GP; Wallace LE
Pain Med; 2017 Jan; 18(1):78-85. PubMed ID: 27373304
[TBL] [Abstract][Full Text] [Related]
14. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
Stanos S
Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.
Heyward J; Olson L; Sharfstein JM; Stuart EA; Lurie P; Alexander GC
JAMA Intern Med; 2020 Feb; 180(2):301-309. PubMed ID: 31886822
[TBL] [Abstract][Full Text] [Related]
16. Primary care physician attitudes and perceptions of the impact of FDA-proposed REMS policy on prescription of extended-release and long-acting opioids.
Salinas GD; Robinson CO; Abdolrasulnia M
J Pain Res; 2012; 5():363-9. PubMed ID: 23091393
[TBL] [Abstract][Full Text] [Related]
17. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.
Slevin KA; Ashburn MA
J Opioid Manag; 2011; 7(2):109-15. PubMed ID: 21561034
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
